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Opinion statement
Benign esophageal strictures arise from a diversity of causes, for example esophagogastric
reflux, esophageal resection, radiation therapy, ablative therapy, or the ingestion of a
corrosive substance. Most strictures can be treated successfully with endoscopic dilation
using bougies or balloons, with only a few complications. Nonetheless, approximately one
third of patients develop recurrent symptoms after dilation within the first year. The
majority of these patients are managed with repeat dilations, depending on their com-
plexity. Dilation combined with intra lesional steroid injections can be considered for
peptic strictures, while incisional therapy has been demonstrated to be effective for
Schatzki rings and anastomotic strictures. When these therapeutic options do not resolve
the stenosis, stent placement should be considered. Self bougienage can be proposed to a
selected group of patients with a proximal stenosis. As a final step surgery is an option,
but even then the risk of stricture formation at the anastomotic site remains. This chapter
reviews refractory benign esophageal strictures and the treatment options that are
currently available.
Introduction
Benign esophageal strictures are caused by a diversity of
esophageal disorders or injuries, for example gastro-
esophageal reflux, radiation therapy, ablative therapy,
or the ingestion of a corrosive substance. In addition,
stricture formationmay be a complication of esophageal
resection with gastric tube formation [1, 2]. More than
80–90 % of esophageal strictures can be treated success-
fully with endoscopic dilation using Savary bougies or
balloons. Esophageal dilation is a procedure with a very
low rate of serious complications, mainly bleeding and
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perforation [3–5]. Unfortunately, approximately one
third of patients develop recurrent dysphagia after dila-
tion within the first year. The majority of these patients
are managed with repeat dilations, depending on their
complexity [2, 6].
Simple strictures are considered to be short, focal,
straight, and to allow passage of a normal diameter
endoscope. Examples include Schatzki rings, esophageal
webs, and peptic strictures [7]. Overall, one to three
dilations are sufficient to relieve dysphagia in simple
strictures. Only 25–35 % of patients require additional
sessions, with amaximum of five dilations in more than
95 % of patients [4]. Complex strictures are usually
longer (92 cm), angulated, irregular, or have a severely
narrowed diameter. These strictures are more difficult to
treat and have a tendency to be refractory or to recur
despite dilation therapy. A fair number of complex stric-
tures include circular, anastomotic strictures in the ab-
sence of endoscopic evidence of inflammation [8••, 9].
Other etiologies include radiation induced strictures,
caustic strictures, and photodynamic therapy induced
strictures [7].
Dysphagia is themost common symptom in patients
with a benign esophageal stricture. Remarkably, most
patients do not experience severe weight loss, as can be
seen in malignant esophageal strictures [9]. Treatment
aims to relieve symptoms, with the avoidance of com-
plications and the prevention of recurrences. Still, dila-
tion is the first line option to treat benign esophageal
strictures.When strictures are refractory or recur, dilation
therapy combined with steroid injections, incisional
therapy, stent placement, self-bougienage, or surgery
can be considered [10]. According to the Kochman
criteria, refractory or recurrent strictures are defined as
an anatomic restriction because of a cicatricial luminal
compromise or fibrosis resulting in clinical symptoms of
dysphagia in the absence of endoscopic evidence of
inflammation. This may occur as the result of either an
inability to successfully remediate the anatomic prob-
lem to a diameter of at least 14 mm over five sessions at
two-week intervals (refractory); or as a result of an in-
ability to maintain a satisfactory luminal diameter for
four weeks once the target diameter of 14 mm has been
achieved (recurrent). This definition is not meant to
include patients with an inflammatory stricture (which
will not resolve until the inflammation subsides), or
those with a satisfactory diameter but having dysphagia
on the basis of neuromuscular dysfunction (for example
those with dysphagia due to postoperative and/or
postradiation therapy) [8••].
Treatment of benign esophageal strictures
Dilation
The first step inmanaging benign esophageal strictures remains dilationwith an
inflatable balloon or a (Savary) bougie [4, 9, 11]. In the literature, no differences
have been shown between balloon and bougie dilation in relief of dysphagia
and/or recurrence of dysphagia. Also no differences have been shown in the risk
of major complications [12–14]. Major complications include perforation,
bleeding, and bacteremia. Perforation risk varies between 0.1% and 0.4% [11].
Although themajority of patients are effectively treatedwith up to five dilations,
approximately 10% of patients need ongoing dilations to become dilation free
[8••, 15]. In order to reduce the number and burden of endoscopic dilations to
become dysphagia free, various endoscopic treatment options have been
suggested.
Dilation combined with steroid injection
Adding steroid injection to endoscopic dilation into the stricture followed by
dilation to avoid recurrent dysphagia has been reported to prevent stricture
recurrence. This method, advocated since 1966, has shown encouraging results
in patients with peptic strictures [16]. However,most of these studies were small
and uncontrolled [17–19]. Randomized trials are unfortunately limited and
small-sized [20–22]. Camargo, et al., randomized 14 patients with corrosive
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strictures allocated to steroid injection or placebo [20]. These authors did not
find a difference in dilation frequency or recurrent dysphagia between the two
groups. In another randomized trial, 21 patients with strictures of different
etiologies were included. An increase in the dysphagia free period and periodic
dilation index was reported in the steroid arm, but there was not a difference in
the total number of dilations. Another study demonstrated a decrease in mean
dilation frequency in patients with peptic strictures, from six dilations in the
control group to two dilations in the steroid group after one year follow up [21].
Ramage, et al., performed a randomized trial comparing dilation to
intralesional 4-quadrant injection of triamcinolone injections [22]. Thirty pa-
tients with peptic strictures with recurrent dysphagia after at least one dilation
session were included. They concluded that dilation combined with steroid
injection and gastric acid suppression therapy reduced the number of repeat
dilations and the dysphagia free period, with re-dilation rates of 13 % in the
steroid group versus 60 % in the control group (p=0.01).
Hirdes, et al., recently evaluated the efficacy of intralesional triamcinolone
injections combined with endoscopic dilation in a relatively large group of
patients with anastomotic strictures [23•]. A total of 60 patients with untreated
cervical anastomotic esophageal strictures after esophagectomy with gastric
tube reconstruction and dysphagia for at least solid food were enrolled and
randomized to dilation with or without steroid injections. They concluded that
adding intralesional steroid injections to Savary dilation in patients with un-
treated benign anastomotic esophageal strictures did not result in a clinical
benefit. Furthermore, an increased incidence of candida esophagitis was found
in the remaining esophagus proximal to the anastomosis.
In conclusion, there is evidence that steroid injection in combination with
dilation is able to reduce the risk of recurrent dysphagia in refractory benign
esophageal strictures of peptic origin. Nonetheless, this result comes from
various small-sized studies with poorly defined patient populations. Further-
more the optimal injection dose, technique and frequency remain to be deter-
mined. On the contrary, adding steroid to dilation was not found to be effective
in anastomotic strictures. The pathogenesis of anastomotic strictures differs
from that of peptic strictures, in that the former is due to ischemia whereas the
latter develops as a result of inflammation and ulceration from reflux of gastric
acid [24]. Steroids are suggested to locally inhibit the inflammatory response,
resulting in a reduction of collagen formation [22].
Needle knife incision
Incisional therapy with a needle knife was first reported for the treatment of
Schatzki rings [25, 26]. Subsequently, incisional therapy added to balloon
dilation, or incisional therapy using a polypectomy snare with additional argon
plasma coagulation, were shown to be effective in a small series of patients with
anastomotic strictures, without the occurrence of complications [27–30].
Hordijk, et al., included 20 patients with anastomotic strictures that were
refractory to dilation, and demonstrated that incisional therapy was safe and
effective in simple, short strictures (G10mm) [31]. In another study, 24 patients
with anastomotic strictures without previous dilation were included. They were
treated with endoscopic incisional therapy applying a transparent hood on the
tip of the endoscope to enhance control and safety. After two years of follow up
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87.5 % of the patients were still dysphagia free after one session [32]. In 2009,
Hordijk, et al., randomized 62 patients with a primary anastomotic stricture
after esophagectomy (who were not previously treated with dilation therapy),
to Savary dilation or electrocautery incision. No significant difference in clinical
success rates were detected between the incisional therapy and dilation therapy
arms [33]. Furthermore no complications were observed after incisional thera-
py. So, incisional therapy can be considered as an alternative treatment in
patients with a (relatively) short stenosis (Fig. 1).
Stent placement
Dilation of an esophageal stricture with a balloon or a bougie is usually done
for a period of a few seconds or some minutes. It can, however, be imagined
Fig. 1. Endoscopic view of. a Anastomotic stricture. b Directly
after incisional therapy. c After long term follow up.
50 Esophagus (E Dellon, Section Editor)
that if the dilator can be kept in place for a longer time, the benefits of dilation
may be longer lasting. In the past few years, temporary stent placement has
increasingly been used for refractory benign esophageal strictures. Self-
expandable plastic stents (SEPS) are FDA approved for this indication, and have
been used [34, 35]. Partially and fully covered self-expandable metal stents
(SEMS), although not FDA approved, are also frequently used to treat benign
esophageal strictures. An alternative for SEPS and SEMS is the biodegradable
stent [36], which has the advantage of not requiring removal.
Self-expandable metal stents (SEMS)
Uncovered SEMS were initially used for the treatment of refractory benign
esophageal strictures [37–41]. In more recent years, partially or fully covered
SEMS have become available and are now commonly used for this indication
[35, 40, 42–44]. One of the major drawbacks of uncovered and partially
covered SEMS, is that they are associated with a relatively high complication
rate, mostly due to hyperplastic tissue ingrowth through the stent mesh
resulting in embedding of the stent in themucosa [45]. The complication rate of
uncovered or partially stents has been reported to be as high as 80 %. The most
common complications of these stents is indeed new stricture formation due to
tissue ingrowth, but also stent migration, pain, gastroesophageal reflux if the
stent is positioned across the gastroesophageal junction, and fistula formation
[46]. Tissue ingrowth consists histologically of granulation tissue, but reactive
hyperplasia and fibrous tissue are also seen [47]. Tissue reaction often results in
recurrent dysphagia and may hamper stent removal. On the other hand, par-
ticularlyminor tissue ingrowthmay also reduce the risk of stentmigration (only
12 % vs. 36 % for fully covered SEMS) [35, 48, 49•, 50, 51]. The risk of tissue
ingrowth increases with stenting time, but can already be seen after one to four
weeks. Tissue ingrowth can successfully be treated with the stent-in-stent
method described by Hirdes, et al. Using this technique a fully covered stent is
placed inside the previously placed embedded stent [49•]. The fully covered
stent should have a length that at least overlaps and to have a size that is equal,
or slightly larger than, the initially placed partially covered stent. Over a period
of 10–14 days pressure necrosis of the hyperplastic tissue occurs as a result of
friction. Hereafter, both stents can usually easily be removed.
To overcome the problem of stent ingrowth, fully covered stents (SEMS or
SEPS) seem preferable for benign esophageal strictures. Currently, data on the
use of fully covered SEMS is limited. In the first study performed by Eloubeidi,
et al., a total of 36 stents were placed in 31 patients over a period of 16 months.
A clinical success rate of 29%was reported. A total of 47%of these patients had
no recurrence of dysphagia [48]. Bakken, et al., performed a retrospective study
including seven patients with a refractory stricture. Stent migration occurred in
more than half of the patients. None of the patients were treated successfully
[52]. In 2011, Eloubeidi, et al., included 10 patients with a benign refractory
esophageal stricture. A clinical success rate of 21 % was reported, with a
migration rate of 10 % [53]. A new generation of fully covered SEMS, the fully
covered Wallflex (Boston Scientific, Natick, MA), was recently evaluated by
Hirdes, et al. They included 15 patients with a refractory benign esophageal
stricture. The migration rate was 35 %, while tissue overgrowth was seen in
20 % of patients. Recurrent dysphagia occurred in all patients after a median of
only 15 days after stent removal. These disappointing results were however
most likely due to the highly refractory patient population in this study [54].
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Self-expandable plastic stents (SEPS)
SEPS have been proposed as an alternative to SEMS to minimize hyperplastic
tissue reflection. In 2010, Repici, et al., performed a pooled data analysis of all
available studies on the use of SEPS for benign esophageal strictures. A total of
130 treated patients were included from 10 studies. Stent placement was
technically successful in 98 % of the patients. In 52 % of patients no further
dilations were required after a median follow up of 13 months after stent
removal. Median stenting time in these studies was not reported. In patients
with a proximal stricture the success rate was somewhat lower (33%). As can be
expected, due to the fully covered stent design, a relatively high percentage
(24 %) of stents migrated within four weeks, resulting in a high rate of
endoscopic re-interventions (21 %). Major complications were seen in 9 % of
patients. One patient died of massive bleeding [55]. More recently, Ham, et al.,
published an updated systematic review. A total of 172 patients with a benign
esophageal stricture were included and treated with SEPS. They found a tech-
nical success rate of 98 % and a clinical success rate of 45 % with a rate of early
stent migration of 31 % [56]. It can be concluded that SEPS are effective for the
treatment of refractory esophageal strictures, but the design needs further
improvement to reduce the risk of migration. Moreover, the stent has a high
radial and axial force, which may be the cause of an increased risk of stent-
related complications to the esophageal wall, for example severe bleeding.
In general, more studies are needed to compare different stent designs head-
to-head for the treatment of benign esophageal strictures. An alternative treat-
ment option that has recently been introduced is the placement of a biode-
gradable stent (Fig. 2). Van Boeckel, et al., compared biodegradable stents with
SEPS, i.e., Polyflex stent (Boston Scientific, Natick, MA), in a nonrandomized
head-to-head comparison. They found that both SEPSs and biodegradable
stents provided long-term relief of dysphagia in 30% and 33%, respectively, of
patients with a refractory esophageal stricture. However, biodegradable stents
require fewer procedures than SEPSs [57•].
Biodegradable stents
Only a small number of cohort studies on the use of biodegradable stent
placement in the esophagus have been published, with only a few studies
Fig. 2. Endoscopic view of a peptic stricture with an expanding
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including 10 or more patients [36, 57•, 58–66]. Repici, et al., included over 30
patients with a refractory benign esophageal stricture and placed an Ella BD
stent (Ella CS, s.r.o., Czech Republic). Complete relief of dysphagia was re-
ported in 43 % of patients after a median follow up of 53 weeks [36]. In this
study, eight (26%) patients had recurrent dysphagia resulting from a recurrence
of the stricture. No major complications were seen. In the above-mentioned
study, van Boeckel, et al., reported complete relief of dysphagia in 33 % of
patients treated with a biodegradable stent after a median of 166 days. In this
study, major complications occurred in four (22 %) patients (two hemorrhage
and two severe retrosternal pain) [57•]. Ibrahim, et al., included 20 patients
treated with an Ella BD stent. Half of them needed one or more additional
procedures for recurrent dysphagia after six months of follow up [64]. Van
Hooft, et al., also concluded that placement of an Ella BD stent was an effective
one step treatment in 60 % (6 of 10), of patients with an anastomotic stricture
in the esophagus. No major complications were reported [66]. The other 40 %
of the patients required endoscopic dilation because of stricture related recur-
rent dysphagia. Recently, Hirdes, et al., reported the efficacy and safety of
sequential Ella BD stent placement in 28 patients with a refractory benign
strictures [58]. A total of 59 biodegradable stents were placed in these patients.
After initial stent placement patients remained dysphagia free for a period of
90 days, while after six months still 25 % of patients were dysphagia free. After
placement of a second biodegradable stent in patients with recurrent stricture
formation, patients remained dysphagia free for a median period of 55 days.
After six months only 15 % of these patients were still dysphagia free. After a
third biodegradable stent placement, the median dysphagia free period was
106 days but none of the patients remained dysphagia free after a period of six
months. Major complications occurred in 29 %, 8 %, and 28 % of patients after
one, two, and three Ella BD stents respectively. From these studies it can be
concluded that a single biodegradable stent is only temporarily effective in the
majority of patients. The relatively low radial force and degradable nature of these
stents may contribute to early stricture recurrence [67]. Stent placement was also
found to be associated with considerable complications, like retrosternal pain and
vomiting. However, in selected patients with a refractory benign esophageal stric-
ture, sequential biodegradable stent placement can be an effective alternative to
avoid the burden of frequent serial dilations. Further (prospective), studies in-
cluding larger numbers of patients, and comparing biodegradable stents with fully
covered SEMS (or SEPS), are needed. In those studies patient satisfaction and costs
should be evaluated besides efficacy and safety.
Optimal duration of stent placement in refractory benign esophageal strictures
The optimal duration of stent placement for treating refractory benign esoph-
ageal strictures is unknown, but likely depends on a number of variables, such
as stricture type, severity of the inflammation, stricture length, and stent type.
These factors should be evaluated in all patients. The general principle is to leave
the stent in place until the inflammation is resolved. In strictures longer than
5 cmor those due to ischemic injury, dilation for a period of at least 8–16weeks
is recommended. For shorter strictures and other etiologies shorter stenting
times can be recommended, but still these strictures may also be refractory.
Only fully covered stent designs can safely be removed after a prolonged time of
stenting. When partially covered stents are used, repeat endoscopy should be
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performed at 2–4 week intervals to evaluate embedding of the stent in the wall.
After biodegradable stent placement, a completely different treatment strategy
can be followed. Only when patients treated with a biodegradable stent present
with recurrent dysphagia should a repeat endoscopy be performed. In most
cases thismeans that the stent is dissolved and a new stent, either biodegradable
or SEMS, can be placed.
Treatment selection (algorithm)
In absence of evidence based treatment guidelines for patients with dysphagia
due to refractory benign esophageal strictures [68, 69], an algorithm has been
suggested for the therapeutic management of patients with benign dysphagia
[10, 70], which is shown in Figure 3. Dilation remains the first choice as the
least invasive approach with a low complication rate (0.001–0.040 %) [69]. If
the selected approach is not sufficient a next step in the algorithm should be
discussed with the patient, i.e., dilation with steroids, incisional therapy for
selected strictures, or stent placement. If still refractory, self-bougienage can be
proposed to patients with a stenosis in the proximal esophagus [71, 72]. An
ultimate step in the management of (refractory), benign esophageal strictures
includes surgery, taking into account that even after a surgical solution the risk
of stricture formation remains [24–26]. In our experience, the majority of
benign strictures can be managed by non-surgical means.
Randomized trials are needed to determine the optimal treatment strategy in
patients with refractory and recurrent benign esophageal strictures. One such trial
includes a comparison between Savary or balloon dilation therapy and stent
placement, either a fully covered SEMS or biodegradable stent, to determine
Fig. 3. Recommended treatment scheme for patients with benign esophageal stricture.
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whether stent placement could be positioned at an earlier stage in the treatment
algorithm. Furthermore, biodegradable stents should be compared with fully
covered stent designs (as discussed earlier). Finally, the use of a (locally applied)
treatment aiming to improve oxygenation (anastomotic strictures), and/or to
reduce the inflammatory process in strictures, could be an important step.
Conclusion
The treatment of refractory benign esophageal strictures remains a challenge for
clinicians. Dilation of the stricture with Savary or balloon remains the first step.
Dilation combined with intra lesional injections with steroids can be considered
for peptic stenosis, while incisional therapy is found to be effective for Schatzki
rings and anastomotic strictures. After failure of these therapeutic options stent
placement can be considered. A final step includes self bougienage or surgery.
Following this treatment algorithm means that most patients with a difficult to
treat esophageal stricture can bemanaged without an invasive surgical procedure.
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